Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119131 | 1.00 | GRIK1 (0.36) | GRIK1GRIK2EP300ALDH1A1FFAR3 | |
| Hydrochloric Acid SCHEMBL1155809 | 0.98 | GRIK1 (0.35) | GRIK1GRIK2EP300ALDH1A1 | |
| Bromomethane SCHEMBL7095814 | 0.95 | GRIK1 (0.34) | GRIK1GRIK2 | |
| Acetic Acid SCHEMBL11512956 | 0.95 | GRIK1 (0.34) | GRIK1GRIK2FFAR3 | |
| Chloromethane SCHEMBL124967 | 0.95 | GRIK1 (0.34) | GRIK1GRIK2ALDH1A1 | |
| Sulfuric Acid SCHEMBL1155536 | 0.91 | GRIK1 (0.32) | GRIK1GRIK2 | |
| SCHEMBL8736368 | 0.91 | GRIK1 (0.32) | GRIK1GRIK2 | |
| Acrylic Acid SCHEMBL4974396 | 0.91 | LMNA (0.42) | GRIK1GRIK2ALDH1A1 | |
| Acrylamide SCHEMBL7129210 | 0.86 | ALDH1A1 (0.41) | GRIK1GRIK2ALDH1A1 | |
| SCHEMBL1155347 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114712252-A | Hydrogel microcapsule compatible with cationic daily chemical | 重庆小丸生物科技股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-109983177-A | Polymer is during manufacturing Paper or cardboard for controlling the purposes of deposit formation | 凯米罗总公司 | 2019-07-05 | — | — | CN | claimed |
| US-12312490-B2 | Waterborne, UV curable coating composition for easy-clean coatings | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2025-05-27 | — | — | US | disclosed |
| CN-114761397-B | Benzodiazepine derivatives for the treatment of Respiratory Syncytial Virus (RSV) infection | 辉瑞公司 | 2024-11-05 | — | — | CN | disclosed |
| US-11920052-B2 | Waterborne, UV curable coating composition for easy-clean coatings | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2024-03-05 | — | — | US | disclosed |
| US-20240034906-A1 | Waterborne, UV Curable Coating Composition For Easy-Clean Coatings | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2024-02-01 | — | — | US | disclosed |
| CN-114599748-B | Water-based UV curable coating composition for easy-to-clean coatings | 阿克佐 诺贝尔国际涂料股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| WO-2023077259-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220259455-A1 | Waterborne, UV Curable Coating Composition For Easy-Clean Coatings | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2022-08-18 | — | — | US | disclosed |
| CN-114712252-A | Hydrogel microcapsule compatible with cationic daily chemical | 重庆小丸生物科技股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4023593-A1 | COMPOSITION CONTAINING INORGANIC SOLID ELECTROLYTE, SHEET FOR ALL-SOLID SECONDARY BATTERIES, ALL-SOLID SECONDARY BATTERY, METHOD FOR MANUFACTURING SHEET FOR ALL-SOLID SECONDARY BATTERIES, AND METHOD FOR MANUFACTURING ALL-SOLID SECONDARY BATTERY | FUJIFILM Corporation (JP) | 2022-07-06 | — | — | EP | disclosed |
| EP-2298776-A1 | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7728029-B2 | Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1999114-A2 | PYRAZOLES AS 11-BETA-HSD-1 | F. Hoffmann-la Roche AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107470-A2 | PYRAZOLES AS 11-BETA-HSD-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | ANDERSON KEVIN WILLIAM | 2007-09-27 | — | — | US | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| EP-0503958-B1 | Heterocyclic compounds and their production | NIPPON PAINT CO LTD (JP) | 1998-09-23 | — | — | EP | disclosed |
| US-5496943-A | USING UNSATURATED ACYLISOCYANATE COMPOUNDS TO FORM OXAZOLINES, PYRANS WITH AMINOCARBONYLHETERO SUBSTITUTION AND GLUTARIMIDE DERIVATIVES AS CHEMICAL INTERMEDIATES | NIPPON PAINT CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0503958-A2 | Heterocyclic compounds and their production | Nippon Paint Co., Ltd. (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD3B2, HSD3B1, HSD17B2 | GRIK1 1223/4885GRIK2 1147/4885EP300 947/4885 |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | MCHR1, MCHR2, MC1R | GRIK1 773/4885GRIK2 1237/4885EP300 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.